News

Published on 13 Nov 2023 on Zacks via Yahoo Finance

How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%


Article preview image

Shares of Tango Therapeutics, Inc. (TNGX) have gained 8.7% over the past four weeks to close the last trading session at $8.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18 indicates a potential upside of 115.3%.

The mean estimate comprises three short-term price targets with a standard deviation of $2. While the lowest estimate of $16 indicates a 91.4% increase from the current price level, the most optimistic analyst expects the stock to surge 139.2% to reach $20. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

NASDAQ.TNGX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In t...

Insider Monkey · via Yahoo Finance 24 Nov 2024

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity On Thursday, Tango Therap...

Benzinga via Yahoo Finance 23 May 2024

Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know

Wall Street expects a year-over-year increase in earnings on higher revenues when Tango Therapeut...

Zacks via Yahoo Finance 7 May 2024

Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results

Financial Position: Tango Therapeutics Inc (NASDAQ:TNGX) ended 2023 with a robust cash position o...

GuruFocus.com via Yahoo Finance 20 Mar 2024

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zack...

Zacks via Yahoo Finance 18 Mar 2024

11 Oversold Biotech Stocks To Buy Right Now

In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip...

Insider Monkey via Yahoo Finance 17 Mar 2024

12 Most Promising Cancer Stocks According to Analysts

In this piece, we will take a look at the 12 most promising cancer stocks according to analysts. ...

Insider Monkey via Yahoo Finance 18 Dec 2023

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%

Tango Therapeutics, Inc. (NASDAQ:TNGX) shares have had a really impressive month, gaining 25% aft...

Simply Wall St. via Yahoo Finance 13 Dec 2023

How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%

Shares of Tango Therapeutics, Inc. (TNGX) have gained 8.7% over the past four weeks to close the ...

Zacks via Yahoo Finance 13 Nov 2023

Need To Know: Analysts Are Much More Bullish On Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenues

Tango Therapeutics, Inc. (NASDAQ:TNGX) shareholders will have a reason to smile today, with the a...

Simply Wall St. via Yahoo Finance 9 Nov 2023